Fig 1.
PD: peritoneal dialysis; HD: hemodialysis; ESAs: erythropoiesis-stimulating agents.
Table 1.
Main baseline characteristics of patients included in the study.
Fig 2.
Mean hemoglobin levels of Roxadustat and ESAs groups over time.
* P < 0.05 versus baseline level. Hb: hemoglobin; ESAs: erythropoiesis-stimulating agents.
Fig 3.
Mean total cholesterol levels over time in the roxadustat group (A) and ESAs group (B) according to the statins subgroup.
Mean LDL-cholesterol levels over time in the roxadustat group (C) and ESAs group (D) according to the statins subgroup. Mean HDL-cholesterol levels over time in the roxadustat group (E) and ESAs group (F) according to the statins subgroup. * P < 0.05 versus the corresponding baseline level. LDL: Low-Density Lipoprotein; HDL: High-Density Lipoprotein; ESAs: erythropoiesis-stimulating agents.
Fig 4.
(A) Changes of left ventricular ejection fraction over time in Roxadustat and ESAs groups.
(B) Changes of BNP over time in Roxadustat and ESAs groups. (C) Changes of LVESD over time in Roxadustat and ESAs groups. (D) Changes of LVEDD over time in Roxadustat and ESAs groups. * P < 0.05 versus the corresponding baseline level, **P < 0.01 versus the corresponding baseline level, ***P < 0.001 versus the corresponding baseline level. BNP: brain natriuretic peptide; LVESD: left ventricular end- systolic dimension; LVEDD: left ventricular end-diastolic dimension; ESAs: erythropoiesis-stimulating agents.
Fig 5.
Morisky score for ESAs group and Roxadustat group.
**P < 0.01 versus the ESAs group. ESAs: erythropoiesis-stimulating agents.
Fig 6.
(A) Monthly drug costs of patients in the ESAs group and Roxadustat group.
(B) Additional monthly costs of measures to correct renal anemia in addition to ESAs and roxadustat. ****P < 0.0001 versus the ESAs group.
Table 2.
Summary of clinical outcomes after 9 months.